anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This review delves into the entorhinal cortex (EC) as a central player in the pathogenesis of Alzheimer's Disease (AD), emphasizing its role in the accumulation and propagation of tau pathology. It elucidates the multifaceted functions of the EC, encompassing memory formation, spatial navigation, and olfactory processing, while exploring how disruptions in these processes contribute to cognitive decline in AD. The review discusses the intricate interplay between tau pathology and EC vulnerability, highlighting how alterations in neuronal firing patterns and synaptic function within the EC exacerbate cognitive impairments. Furthermore, it elucidates how specific neuronal subtypes within the EC exhibit differential susceptibility to tau-induced damage, contributing to disease progression. Early detection methods, such as imaging techniques and assessments of EC blood flow, are examined as potential tools for identifying tau pathology in the preclinical stages of AD. These approaches offer promise for improving diagnostic accuracy and enabling timely intervention. Therapeutic strategies targeting tau pathology within the EC are explored, including the clearance of pathological tau aggregates and the inhibition of tau aggregation processes. By understanding the molecular and cellular mechanisms underlying EC vulnerability, researchers can develop more targeted and effective interventions to slow disease progression. The review underscores the importance of reliable biomarkers to assess disease progression and therapeutic efficacy in clinical trials targeting the EC. Ultimately, it aims to contribute to the development of more effective management strategies for AD, emphasizing the translation of research findings into clinical practice to address the growing societal burden of the disease.
As with any NSAID, caution should be exercised in treating the elderly (65 years and older) and when increasing the dose (see WARNINGS).

In etodolac clinical studies, no overall differences in safety or effectiveness were observed between these patients and younger patients. In pharmacokinetic studies, age was shown not to have any effect on etodolac half-life or protein binding, and there was no change in expected drug accumulation. Therefore, no dosage adjustment is generally necessary in the elderly on the basis of pharmacokinetics (see CLINICAL PHARMACOLOGY, Special Populations).

Elderly patients may be more sensitive to the antiprostaglandin effects of NSAIDs (on the gastrointestinal tract and kidneys) than younger patients (see WARNINGS). In particular, elderly or debilitated patients who receive NSAID therapy seem to tolerate gastrointestinal ulceration or bleeding less well than other individuals, and most spontaneous reports of fatal GI events are in this population.

Etodolac is eliminated primarily by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see WARNINGS,  Renal Effects).
A compound of formula I where: -Z  is  a  group selected from substituted and unsubstituted alkyl,   alkenyl,  alynl,  cycloalkyl,  heterocycle,   aryl, heteroaryl,  CH2OH and C(O)R. The number of  carbons  ranges from 1 to 12. - R is substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heteroaryl. -  Y  is  a  lipophilic group selected from substituted  and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl  and heteroaryl. The number of carbons range from 6 to 20. - X1 is a structural unit connecting CH2NC(O). - X2 is a basic group having a pKa greater than about 8, and is selected from: o  Substituted  or  unsubstituted alkyl,  alkenyl,  alkynyl, cycloalkyl, aryl and heteroaryl such that the atom count  in the  chain portion of the unit linking the central  nitrogen to X2 ranges from 3 to 8.
Seed virus for preparation of inactivated swine parvo virus vaccine was sepatated from intestinal emulsion soln. of a mummyborn pig and was repeatedly transcultured.  The seed virus was inoculated into a 30-50 day pregnant swine without an antibody against swine parvo virus.  After 2-3 weeks, pig embryo was pick out by application surgical operation or artificial premature delivery method and 10% emulsion soln. was made from its intestines with phosphate buffer and was centrifuged. β-Propionolactone was added to the supernatant to adjust the final concentration to 0.2 % and the mixture was inactivated with stirring for 18hrs. at 80≰C.
Background: As the available treatments for moderate-to-severe atopic dermatitis (AD) expand, understanding patient and physician preferences becomes crucial for informed decision-making. Objective: To quantify patient and physician preferences for biologics and oral systemic AD treatment attributes. Materials and methods: We conducted a cross-sectional, online discrete choice experiment (DCE) involving 306 AD patients and 206 physicians throughout the United Kingdom and Germany. Qualitative interviews identified the key attributes for inclusion in the DCE. Each choice task comprised two hypothetical patient profiles. Data were analyzed using a random-parameters logit model. Results: Results indicated a significant emphasis on efficacy, with reducing sleep disturbance and itch ranking first and second among patients, and the reverse for physicians. Time to itch relief was the third most important efficacy attribute for both groups, but relatively more important for patients than for physicians. For both groups, the risk of eye problems was the most important safety concern of those included. Mode of administration was not of great importance compared to efficacy and safety attributes. Conclusions: Our findings suggest patients prioritize sleep disturbance, an attribute not captured in prior preference studies in AD, time to itch relief and itch. These findings emphasize the importance of addressing sleep-related issues, whilst also targeting fast itch control, to enhance patients' well-being.
PROBLEM TO BE SOLVED: To obtain the subject preservative agent safe, excellent in colorectal preservative effects in a low concentration, and capable of being properly adopted into daily eating habits to be reasonably ingested, by compounding sericin and its hydrolyzate as ingredients. SOLUTION: This colorectal cancer preservative agent contains sericin and/or its hydrolyzate as ingredients. The sericin is preferably derived from cocoons or raw silk. The sericin is obtained as an unhydrolyzed product, for example, by extracting the cocoons or raw silk with water, mixing the extract with a water-soluble organic solvent, such as methanol, ethanol and dioxane, to precipitate the sericin, then filtering and drying the precipitate to form sericin powder. The sericin hydrolyzate is obtained by partially hydrolyzing the sericin contained in cocoons or raw silk with an acid, a base or the like, then extracting, mixing, etc. and following the procedures similar to the above. The sericins are preferably added to the preservative agent in an amount of 0.1-50 wt.%. The sericins are preferably administered at a daily dose of 1-1,000 mg per kg of the body weight of the patient.
A large vessel occlusion (LVO) alert generated by a point-of-care diagnostic system is received. The LVO alert is representative of a probability of an LVO event in a patient. A mapping coordinate is received. A database of care centers proximate to the mapping coordinate is accessed. A preferred care center from the database is selected based at least on a treatment capability associated with the preferred care center and a distance of the care centers to the mapping coordinate. An LVO event notification is transmitted to initiate stroke medical care.
A derivative of motivational interviewing (MI), which is a patient-centered, collaborative counseling approach to strengthen an individual's intrinsic motivation towards a positive behavior change. BMI is intended for healthcare providers with limited time (5-10 minutes) to support a positive behavior change.
In the present invention, a user information acquisition unit (1) acquires user information including information representing the residence of the user. An appropriate exercise-quantity determining unit (3) refers to an appropriate exercise-quantity database (2) to determine an appropriate quantity of exercise for the user on the basis of the user information. An event database (4) records event information containing information representing the date of event occurrence, information representing the location of event occurrence, and information representing event contents. A travel distance database (5) records information representing the distance of travel from the user residence to the location of event occurrence. A travel plan candidate generation unit (6) acquires event information by referring to the event database (4) and acquires information representing travel distance from the travel distance database (5). Then, on the basis of the event information and the information representing travel distance, the travel plan candidate generation unit generates travel plan candidates wherein the planned amount of exercise falls in a predetermined range from the appropriate quantity of exercise for the user. A travel plan candidate presentation unit (8) presents travel plan candidates to the user.
The present invention relates to adenovirus vectors and their use in DNA delivery systems. The vectors have been designed to maximize their capacity to carry foreign DNA and to minimize the potential of producing replication competent virus. The vectors contain one or more copies of a minimum packaging sequence to direct virus packaging. Optionally, the vectors contain one or more repressor binding sites so that virion production can be selectively inhibited. Specific repression systems include COUP-TF and $I(lac) repressor. A cellular complex, called P complex is also disclosed. This complex functions positively in viral packaging and virus production.
BACKGROUND: Even though robotic therapy is becoming more commonly used in research protocols for lower limb stroke rehabilitation, there still is a significant gap between research evidence and its use in clinical practice. Therefore, the present study was designed assuming that the wearable mobile gait device training for chronic stroke patients might have different effects on functional independence when compared to training with a stationary gait device. The present study aims to examine the effects of gait training with ExoAthlet exoskeleton and Lokomat Free-D on functional independence, functional capacity, and quality of life in chronic stroke patients.
METHODS: The present study included 32 chronic stroke patients. Participants were randomly divided into two groups. Functional independence of patients was evaluated by using Functional Independence Measure (FIM), physical function was assessed by using the 30-second chair stand test (30-CST), functional capacity was measured by using the 6-Minute Walk Test (6MWT), and quality of life was assessed by using Short Form 36 (SF36). All participants underwent a conventional physiotherapy program for eight weeks, three sessions per week, and each session lasted 60 min. After the physiotherapy program, one group received gait training by using ExoAthlet exoskeleton (ExoAtlet 1 model/2019, Russia), while the other group received training by using Lokomat Free-D (Hocoma, Lokomat Pro Free-D model/2015, Switzerland). Participants were assessed at baseline and post-intervention.
RESULTS: Results achieved in this study revealed that there was a statistically significant difference between FIM, 30-CST, 6MWT, and SF36 scores before and after the treatment in both groups (p < 0.05).There was no difference in FIM, 30-CST, and 6MWT results between Exoskeleton ExoAthlet and Lokomat Free-D groups (p > 0.05). However, there was a statistically significant difference between Exoskeleton ExoAthlet and Lokomat Free-D groups in terms of SF-36 sub-parameters "vitality", "mental health", "bodily pain", and "general health perception" (p < 0.05).
CONCLUSIONS: This study demonstrated that the use of ExoAthlet exoskeleton and Lokomat Free-D in addition to conventional physiotherapy, was effective in improving functional independence, physical function, functional capacity, and quality of life among chronic stroke patients. Incorporation of robotic gait aids into rehabilitation for chronic stroke patients might offer significant advantages.
Patients will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
FIELD: medicine. ^ SUBSTANCE: invention relates to regenerative medicine, physiotherapy. Method includes massage, exercise therapy in swimming pool, underwater-vertical traction of lower extremity joints and spine, magneto-therapy, thermo-treatment, balneotherapy. Underwater-vertical traction is realised by suspending load symmetrically on each foot and on waist. In case of hip joint arthrosis load is placed on 5-10 cm above knee, in case of arthrosis of knee joints, 5-10 cm above ankle joint, in case of arthrosis of ankle joint load is suspended on feet. During treatment course gradual growth of load value on each foot from 2 to 3-5 kg, and on waist - from 2 kg to 10-15 kg is provided with preservation of maximal load for some days with following gradual reduction to 2-4 kg on each foot and to 4-8 kg on waist. After load removal patient is left in water in suspended condition under own weight for 10-15 minutes. After 1-1.5 hours, magneto-therapy is carried out. Then realised is thermo-treatment with paraffin-ozokerite applications on joints and waist-sacral area of spine every second day, alternating them with balneotherapy with hydrogen sulfide or bishophite baths. Treatment is carried out in courses in amount 1-4 with 6-8 month interval between them. ^ EFFECT: method ensures treatment efficiency due to increase of joint locomotor function. ^ 3 ex, 7 cl
The patients with severe OSA (AHI\>=30) who do not fulfill the specific exclusion criteria wil be randomized. In the CPAP and diet arm, patients wil receive Continuous Positive air pressure therapy and the regular dietary treatment.
Cerebrovascular complications, including cerebral edema and ischemic and hemorrhagic stroke, constitute the leading cause of maternal mortality associated with preeclampsia. The underlying mechanisms of these cerebrovascular complications remain unclear. However, they are linked to placental dysfunction and blood-brain barrier (BBB) disruption. Nevertheless, the connection between these two distant organs is still being determined. Increasing evidence suggests that the placenta releases signaling molecules, including extracellular vesicles, into maternal circulation. Extracellular vesicles are categorized according to their size, with small extracellular vesicles (sEVs smaller than 200 nm in diameter) considered critical signaling particles in both physiological and pathological conditions. In preeclampsia, there is an increased number of circulating sEVs in maternal circulation, the signaling function of which is not well understood. Placental sEVs released in preeclampsia or from normal pregnancy placentas exposed to hypoxia induce brain endothelial dysfunction and disruption of the BBB. In this protocol, we assess whether sEVs isolated from placental explants cultured under hypoxic conditions (modeling one aspect of preeclampsia) disrupt the BBB in vivo.
Hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, and in mostcasesafter a year of therapy. Serious adverse events include tetany, arrhythmias, and seizures. Hypomagnesemia may lead to hypocalcemia and/orhypokalemia and may exacerbate underlying hypocalcemia in at-risk patients. In most patients, treatment of hypomagnesemia required magnesiumreplacement and discontinuation of the PPI.   
For patientsexpected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia(e.g., diuretics),health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see AdverseReactions ( 6.2)].    
Considermonitoring magnesium and calcium levels prior to initiation of Pantoprazole sodium for injection and periodically while on treatment inpatients with a preexisting risk of hypocalcemia (e.g., hypoparathyroidism). Supplement with magnesium and/or calcium as necessary. Ifhypocalcemia is refractory to treatment, consider discontinuing the PPI.
The Standard BWL group will receive weekly BWL sessions (described in more detail in Intervention section) for 12 weeks, followed by every-other-week and monthly weight loss maintenance sessions from weeks 13-26. BWL content will last for 60 minutes, with an additional 30 minutes in this group devoted to discussing recipes and food preparation.
Physical training program will include: dosed aerobic training program on cycle ergometers and respiratory muscle trainings as in control group. Also patients will get an individualized program for frailty syndrome, with the help of interactive technologies 3 times/week. 30-45 minutes (gait training with Biodex GaitTrainerTM3 with visual and audio feedback, Zebris FDM-T, with the help of which virtual barriers are created, thus simulating real environment for the patient, while performing a cognitive task, for balance training we will use a computerized Biodex board. For strength training we will use equipment HUR based on pneumatic (air pressure) technology.
This is a prospective pilot study of participants who have stable coronary heart disease (CHD). Objectives of this study are to understand whether CVD Secondary Risk Panel scores change from baseline to follow-up (4-12 months after baseline) and actions taken, if any, based upon the results. Participants are surveyed to learn what the test results mean to them and assess if the results affect adherence to therapy and lifestyle choices (diet, exercise, alcohol, and tobacco use). In addition, this study will investigate the characteristics of patients that physicians choose to test with the CVD Secondary Risk Panel, and what actions the care team takes because of the results of the test. Medical treatment decisions and recommendations are confirmed by established clinical methods, including blood pressure monitoring, BMI, lipid and CRP measurements, and physician's clinical judgement. Chart abstractions and participants surveys occur at the baseline and follow-up visits, and charts may be abstracted annually for up to 10 years post enrollment.
Several producers of activated water have been in frequent communication with the Principal Investigator (PI) over the last decade or longer. They have regularly supplied their water products to the PI for laboratory testing, including measuring an activity attributed to the absorption of an environmental force, referred to by the PI as KELEA, an abbreviation for Kinetic Energy Limiting Electrostatic Attraction. KELEA is regarded as the source of cellular energy for the body's alternative cellular energy (ACE) pathway. This pathway can provide a non-immunological defense mechanism against infections, presumably including coronaviruses. The proposed study is to test water products from several suppliers, as well as a naturally available source of KELEA activated water in symptomatic individuals who have tested positive by either PCR or antigen testing for Covid-19. The mode of administration will be by inhalation using a nebulizer or diffuser. Several deep inhalations will be taken on 5 occasions daily. Prior to the first inhalation and at the end of the second day of inhalation, swabs will be taken for Covid-19 PCR and/or antigen testing. Randomly allocated participants will either blindly first test the KELEA excellerated water for two days, followed by using water without an elevated level of KELEA and vice versa. The severity of symptoms will also be monitored at the end of each of the two-days periods of inhalation.
Septic lung injury is strongly associated with polarization of M1 macrophages and excessive cytokine release. Fibroblast growth factor (FGF) signaling plays a role in both processes. However, the impact of FGF2 deficiency on macrophage polarization and septic acute lung injury remains unclear. To investigate this, we obtained macrophages from FGF2 knockout mice and examined their polarization and inflammatory cytokine expression. We also eliminated endogenous macrophages using clodronate liposomes and administered FGF2 knockout or WT macrophages intravenously in conjunction with cecal ligation and puncture (CLP) surgery to induce sepsis. In vitro analysis by flow cytometry and real-time PCR analysis demonstrated that FGF2 deficiency resulted in increased expression of M1 markers (iNOS and CD86) and inflammatory cytokines (CXCL1, IL1β, and IL6), especially after LPS stimulation. Additionally, immunofluorescence demonstrated increased nuclear translocation of p65 NF-κB in FGF2 knockout macrophages and RNA-seq analysis showed enrichment of differentially expressed genes in the IL17 and TNFα inflammatory signaling pathways. Furthermore, in vivo experiments revealed that depletion of FGF2 in macrophages worsened sepsis-induced lung inflammation, lung vascular leak, and lung histological injury, accompanied by an increase in CD86-positive cells and apoptosis. Our study suggests that FGF2 deficiency in macrophages plays a critical role in the pathogenesis of septic ALI, possibly because of the enhanced M1 macrophage polarization and production of proinflammatory cytokines. These findings provide empirical evidence for potential therapeutic interventions targeting FGF2 signaling to modulate the polarization of M1 and M2 macrophages in the management of sepsis-induced acute lung injury.
The present invention discloses a preparation method of Chinese medicine haemorrhoids suppository. The following raw materials are made into the extract, condensed, dried, ground and screened, including 160 to 360g of lightyellow sophora root, 80 to 180g of common cnidium fruit, 53 to 120g of corktree bark, 80 to 180g of honeysuckle, 53 to 120g of Chinese gall, 27 to 60g of alumen, 27 to 60g of calamine, 53 to 120g of angelica and 27 to 60g of liquorice. Tween-80, EDTA and sodium bisulfite are added and evenly mixed; greasy molten medium is added to melt and evenly disperse so as to form a fixed shape. The present invention solves the instability of conventional preparation method of suppository. The present invention is used in perianal red swelling and heat pain, bloody stool and other symptoms caused by hemorrhoids (internal hemorrhoids, external hemorrhoids and mixed hemorrhoids). The present invention has the advantages of convenient use, quick effect and accurate curing effect.
PURPOSE:To obtain a skin external preparation with sustainable humectancy when used in the form of face lotion, milky lotion, cream or gel, by combined use of trimethylglycine and a polyol. CONSTITUTION:This skin external preparation with high humectancy is obtained by combined use of trimethylglycine of the formula and a polyol. The polyol is pref. glycerol, diglycerol, propylene glycol, 1,3-butylene glycol, or polyethylene glycol. It is preferable that the contents of the trimethylglycine and polyol in this skin external preparation be 0.01-10 (pref. 0.1-3) wt.% and 0.01-60 (pref. 5-40) wt.%, respectively.